Skip to main content
×
Home
About Us
Company Summary
Senior Management
The Board
Corporate Governance
Board Charter
Audit & Risk
Remuneration & Nominations
Code of Conduct
Continuous Disclosure
Risk Management
Shareholder Communication
Securities Trading
Board & Executive Evaluation
Diversity
Therapeutic Areas
Technology
MSCs
Immunotherapy
Sygenus
Product Pipeline
Pipeline Overview
Human Health
Progenza
Human Cancer Vaccine
Sygenus
Animal Health
CryoShot Canine
Kvax
Trials
Investors
ASX announcements
Financials
Analyst Coverage
Events & Presentations
Investor Relations Contact
Subscribe
News
2019
2018
2017
2016
2015
2014
2013
Contact
Home
About Us
Company Summary
Senior Management
The Board
Corporate Governance
Therapeutic Areas
Technology
MSCs
Immunotherapy
Sygenus
Product Pipeline
Pipeline Overview
Human Health
Animal Health
Trials
Investors
ASX announcements
Financials
Analyst Coverage
Events & Presentations
Investor Relations Contact
Subscribe
News
2019
2018
2017
2016
2015
2014
2013
Contact
Home
Investors
ASX announcements
2015
ASX announcements
2020
2019
2018
2017
2016
2015
2014
2013
Date
Title
15/12/2015
Patent granted for cancer vaccine technology
07/12/2015
Corporate Presentation for Austrade Mission on Regenerative Medicine Opportunities in Japan
07/12/2015
Regeneus to present at Austrade Mission on Regenerative Medicine Opportunities in Japan
26/11/2015
Regeneus initiates canine cancer vaccine trial on lymphoma at SASH
24/11/2015
Breakthrough technology for high potency stem cells opens door for next generation cell therapies
11/11/2015
Key patent granted for allogeneic stem cell technology platform
09/11/2015
Results of 2015 Regeneus Annual General Meeting
09/11/2015
Presentation to shareholders at 2015 AGM
09/11/2015
2015 Annual General Meeting Chairman’s Address
05/11/2015
Stem cells have positive results on early orthopaedic developmental disease in Yearling Thoroughbreds
02/11/2015
Regeneus partners with leading animal health company on stem cell therapy for dogs
27/10/2015
First patient safely treated in cancer vaccine trial
13/10/2015
Regeneus receives R&D tax incentive refund of $3.4m
08/10/2015
Notice of Annual General Meeting 9 November 2015 and Explanatory Statement
04/09/2015
Restricted securities to be released from escrow
02/09/2015
Date of Annual General Meeting
31/08/2015
Regeneus reports 2015 full-year results and business update
31/08/2015
Financial year 2015 full-year results and business update presentation
10/08/2015
First patient treated in Progenza stem cell trial for knee osteoarthritis
25/05/2015
Regeneus receives approval for personalised cancer immunotherapy trial
22/04/2015
Regeneus receives approval for Progenza stem cell trial for osteoarthritis
07/04/2015
Regeneus achieves key stem cell manufacturing milestone for clinical trial
23/03/2015
Regeneus to present at 3rd Annual Regenerative Medicine Investor Day March 25 in New York
09/03/2015
Regeneus reports positive preclinical results for off-the-shelf cell therapy treatment for osteoarthritis
23/02/2015
New Director joins Regeneus Board of Directors
19/02/2015
Regeneus 2015 Half Year Results